Influence of ABCB1 polymorphisms and serum concentrations on venlafaxine response in patients with major depressive disorder.
- Resource Type
- Article
- Authors
- Ozbey, Gul; Celikel, Feryal Cam; Cumurcu, Birgul Elbozan; Kan, Derya; Yucel, Berna; Hasbek, Ekrem; Percin, Ferda; Guzey, Ismail Cüneyt; Uluoglu, Canan
- Source
- Nordic Journal of Psychiatry. Apr2017, Vol. 71 Issue 3, p230-237. 8p.
- Subject
- *THERAPEUTICS
*MENTAL depression
*VENLAFAXINE
*PHARMACODYNAMICS
*ANTIDEPRESSANTS
*PHARMACOKINETICS
*DRUG efficacy
- Language
- ISSN
- 0803-9488
Background:The pharmacokinetics and the pharmacodynamics of antidepressants show large inter-individual variations which result in unpredictable clinical responses. Aim:The aim of the study was to examine the effect ofABCB1polymorphisms and the serum concentrations on the efficacy and tolerability of venlafaxine in patients with major depressive disorder (MDD). Methods:Fifty-two outpatients who met the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for MDD were recruited for the study. The severity of depression was assessed using the 17-item Hamilton Rating Scale for Depression scale (HDRS17) and tolerability was assessed based on a query regarding side-effects for 6 weeks. TheABCB1C3435T/A and G2677T/A polymorphisms were genotyped by PCR/RFLP and steady-state serum venlafaxine concentrations were measured by high-performance liquid chromatography. Results:Patients with the TT genotype for the C3435T and the TT/TA genotype for the G2677T/A polymorphism showed significantly higher frequencies in venlafaxine-induced akathisia. This relationship was not observed for efficacy. As regards serum venlafaxine concentrations, patient groups showed no significant differences in efficacy and tolerability. Conclusion:The results suggest that individuals with the TT-TT/TA genotypes for the C3435T-G2677T/A polymorphisms ofABCB1may be pre-disposed to a risk of akathisia. [ABSTRACT FROM AUTHOR]